Taltz
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Taltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17. It gained approval from the US Food and Drug Administration for the treatment of adults with moderate to severe plaque psoriasis in March 2016, followed by EU and Japanese approvals in April 2016. Taltz is also approved for the treatment of psoriatic arthritis in the US, Japan, and EU.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Taltz : Axial spondyloarthritis (axSpA)
17 Taltz : Psoriatic arthritis (PsA)
29 Taltz : Psoriasis
LIST OF FIGURES
9 Figure 1: Taltz for axial spondyloarthritis – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Taltz in axial spondyloarthritis
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Taltz in axial spondyloarthritis
14 Figure 4: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
25 Figure 5: Taltz for psoriatic arthritis – SWOT analysis
26 Figure 6: Datamonitor Healthcare’s drug assessment summary of Taltz for psoriatic arthritis
27 Figure 7: Datamonitor Healthcare’s drug assessment summary of Taltz for psoriatic arthritis
42 Figure 8: Taltz for psoriasis – SWOT analysis
43 Figure 9: Datamonitor Healthcare’s drug assessment summary of Taltz in psoriasis
44 Figure 10: Datamonitor Healthcare’s drug assessment summary of Taltz in psoriasis
LIST OF TABLES
6 Table 1: Taltz drug profile
7 Table 2: Taltz Phase III trials in axial spondyloarthritis
15 Table 3: Taltz sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
18 Table 4: Taltz drug profile
20 Table 5: Taltz Phase III data in psoriatic arthritis
24 Table 6: Taltz ongoing late-phase trials in psoriatic arthritis
30 Table 7: Taltz drug profile
32 Table 8: Taltz pivotal trial data in psoriasis
40 Table 9: Taltz ongoing late-phase clinical trials in psoriasis
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Otezla 
Sign up to the